Seeking Alpha

fenquarry

fenquarry
Send Message
View as an RSS Feed
View fenquarry's Comments BY TICKER:
Latest  |  Highest rated
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    Algeta:NO is in the process of being taken out by Bayer for $2.9 billion (which is a market cap well above Actinium's current one of less than a puny $200 million) --- that's $67 for each Algeta share. Algeta looks much like Actinium, having two radioimmunotherapy meds - one commercial, with the second only in the planning stage. Actinium, while not yet commercial has its two in the clinic: one with a Phase III study imminent, the other at Phase I/II. There appears to me tremendous upside for ATNM - I'm hoping any takeout occurs later rather than sooner to give ATNM stock a chance to rise to a level approaching what it is really worth.
    Jan 12 12:49 PM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    In the article referenced in John's Jan. 10 comment, Merck is named as a big pharma player potentially in the hunt for smaller biotechs. They already own a slice of Actinium as a result of a chain of acquisitions stretching back to the Organon unit of Akzo Nobel. The main driver of the alpha emitter technology embodied in Actinium's ACTIMAB med was Maurits Geerlings, Sr., Executive VP for Research at Akzo in the early 1990s.
    Jan 11 01:10 PM | Likes Like |Link to Comment
  • Actinium Pharma In Play After Major Update [View article]
    New item on Ahttp://http://bit.ly/1aKgbUT.
    Jan 9 12:36 PM | Likes Like |Link to Comment
  • Actinium Pharmaceuticals: A Cancer Immunotherapy Company With Momentum [View article]
    New item on ATNM: http://bit.ly/1aj9VqE.
    Jan 9 12:34 PM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    New news item on ATNM: http://bit.ly/1aj9VqE
    Jan 9 12:33 PM | Likes Like |Link to Comment
  • Algeta - Clear Upside Without The Binary Risk [View article]
    I invested in Algeta last February in view of an existing investment in the only other alpha emitter radioimmunotherapy company on the planet, Actinium Pharmaceuticals (ATNM on the OTCBB). I like ATNM very, very much --- they take what I term a "cruise missile" approach to fighting cancer and have been successful thus far in the clinic.
    Dec 10 03:25 PM | 1 Like Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    Radioimmunotherapy, which @ActiniumPharma is using to treat cancer might be effective against AIDS http://bit.ly/1f2szUg
    Dec 6 06:55 AM | Likes Like |Link to Comment
  • Actinium Pharma In Play After Major Update [View article]
    Forgot to give link to Abstract in last comment --- here it is: http://bit.ly/1apCLRR .
    Dec 2 01:27 PM | Likes Like |Link to Comment
  • Actinium Pharma In Play After Major Update [View article]
    ATNM will report on clinical data from their ACTIMAB trial this Sat. (Dec. 7). An abstract has already been published.
    Dec 2 01:24 PM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    On Sat. Dec. 7, ATNM will present new data on Actimab trial. Here's link to abstract giving synopsis: http://bit.ly/1apCLRR.
    Dec 2 08:02 AM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    Yes - as far as know ATNM is the only company (other than Algeta) with alpha emitter cancer therapy agents in active development in the clinical trial stage. The Algeta/Bayer deal if it goes through will be in the area of US$ 2.4 billion. ATNM's market cap is much, much lower so there's still a lot of upside potential in the stock.
    Nov 26 09:19 AM | Likes Like |Link to Comment
  • Actinium Pharma In Play After Major Update [View article]
    Algeta, the only other alpha emitter cancer therapy company,today (Nov. 26, 2013) received an acquisition offer from their partner (Bayer) for US$ 2.4 billion. Actinium's market cap is a lowly 130 million US$ --- there's much upside potential there!
    Nov 26 09:19 AM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    Algeta, the closest company to Actinium in terms of technology, has just announced an acquisition request from Bayer!
    Nov 26 08:26 AM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    Further to my earlier comment about Dr. Nicholson: I recollect that Merck is currently the second largest shareholder of Actinium stock after Memorial Sloan Kettering. Merck acquired he stock position when it merged with Schering Plough who had earlier acquired Akzo Nobel's health care companies a few years earlier. The beginnings of Actinium can be traced back to the 1990s when Maurits Geerlings, an Akzo Nobel executive (and co-inventor of the Actinium technology) formed Actinium's predecessor company after Akzo Nobel showed no interest in getting into an oncology business.
    Oct 2 08:56 AM | Likes Like |Link to Comment
  • Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals [View article]
    Dr. C. David Nicholson of Merck currently sits on the Board of Actinium Pharmaceuticals.
    Oct 2 08:40 AM | Likes Like |Link to Comment
COMMENTS STATS
23 Comments
2 Likes